News

Cell therapy breakthroughs in cancer treatment

April 30, 2024

The Translational Research Unit at the Section for Cellular Therapy based in Norway recently published two groundbreaking studies showcasing the potential of cell-based therapies in combating cancer. The research was developed in the labs of Oslo Cancer Cluster Incubator.

Lytix and Curida: Growth and innovation

April 23, 2024

Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.

Sammen om superklynge

April 17, 2024

De fire helseklyngene gikk denne uka sammen om et høringsinnspill til Stortinget.

Results from breast cancer screening pilot

April 15, 2024

A clinical pilot for personalised risk-based breast cancer screening has been conducted as part of the AnteNOR project. Here are some of the results.

Har partiene en kreftpolitikk?

April 10, 2024

During the breakfast seminar The Future of Cancer Politics four politicians discussed possible health- and cancer policies in their coming party programmes. The seminar was held in Norwegian.

DoMore Diagnostics secures EUR 10 million grant

March 19, 2024

In a great achievement, DoMore Diagnostics has been awarded the prestigious EIC Accelerator grant totalling EUR 10 million.

One of Europe’s Leading Start-up Hubs

March 14, 2024

Oslo Cancer Cluster Incubator made the Financial Times Europe’s Leading Start-up Hubs list.

What does it take to make it?

March 11, 2024

What does it take to make it for new biotech companies?

Advancing Cancer Research in Norway: Eli Lilly’s SUNRAY-01 Study

March 5, 2024

Eli Lilly selected Norway as the site for its groundbreaking study project, despite the decline of the recent year's number of clinical cancer trials.